Advancing the Global Treatment of

Niemann-Pick Type C

Focusing on the treatment and management of

Niemann-Pick Type C – a lysosomal storage disease.

Advancing the Global Treatment of Niemann-Pick Type C

tophcpaboutAt NP-C Therapeutics we are focused on the treatment and management of Niemann-Pick Type C, a lysosomal storage disease affecting an estimated 1 : 150,000 people worldwide.  Approximately 50% of cases present before 10 years of age.

NP-C Technology

NP-C Therapeutics, LLC technology was licensed from Notre Dame in August 2014.  The target treatment is a novel combination of three existing drugs with the potential for extension to other lysosomal storage diseases.